| Literature DB >> 34065456 |
Iris Azami-Conesa1, María Teresa Gómez-Muñoz1, Rafael Alberto Martínez-Díaz2.
Abstract
Leishmaniasis are neglected diseases caused by several species of Leishmania that affect humans and many domestic and wild animals with a worldwide distribution. The objectives of this review are to identify wild animals naturally infected with zoonotic Leishmania species as well as the organs infected, methods employed for detection and percentage of infection. A literature search starting from 1990 was performed following the PRISMA methodology and 161 reports were included. One hundred and eighty-nine species from ten orders (i.e., Carnivora, Chiroptera, Cingulata, Didelphimorphia, Diprotodontia, Lagomorpha, Eulipotyphla, Pilosa, Primates and Rodentia) were reported to be infected, and a few animals were classified only at the genus level. An exhaustive list of species; diagnostic techniques, including PCR targets; infected organs; number of animals explored and percentage of positives are presented. L. infantum infection was described in 98 wild species and L. (Viania) spp. in 52 wild animals, while L. mexicana, L. amazonensis, L. major and L. tropica were described in fewer than 32 animals each. During the last decade, intense research revealed new hosts within Chiroptera and Lagomorpha. Carnivores and rodents were the most relevant hosts for L. infantum and L. (Viannia) spp., with some species showing lesions, although in most of the studies clinical signs were not reported.Entities:
Keywords: Leishmania; host; one health; reservoir; wild mammal; wildlife; zoonoses
Year: 2021 PMID: 34065456 PMCID: PMC8160881 DOI: 10.3390/microorganisms9051101
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Zoonotic species of the genus Leishmania and their main characteristics (adapted from Ahoundi et al., 2016 and 2017 [4,5]).
| Section | Subgenus | Species | Clinical Disease in humans | Geographic Area |
|---|---|---|---|---|
| Euleishmania |
|
| CL, DCL | Ethiopia, Kenya |
|
| CL, DCL, MCL | Bolivia, Brazil and Venezuela | ||
|
| VL, PKDL | Central Africa, South Asia, Middle East, India and China | ||
|
| VL, CL | North Africa, South Europe, Middle East, Central Asia and North, Central and South America | ||
|
| CL | Central and North Africa, Middle East and Central Asia | ||
|
| CL, DCL | USA, Mexico, Ecuador, Peru and Venezuela | ||
|
| CL, VL | Central and North Africa, Middle East, Central Asia and India | ||
|
| CL | Northern South America | ||
|
|
| CL, MCL | Brazil, Bolivia, Peru, Guatemala and Venezuela | |
|
| CL, MCL | Bolivia, Brazil, French Guyana and Suriname | ||
|
| CL | Brazil, Bolivia and Peru | ||
|
| CL | Brazil | ||
|
| CL | Brazil, French Guyana | ||
|
| CL, MCL | Brazil, Panama, Venezuela and Colombia | ||
|
| CL, MCL | Peru, Bolivia | ||
|
| CL | Brazil | ||
| Paraleishmania |
| CL, VL | Colombia |
Zoonotic species included in the systematic review are in bold. Clinical forms in humans: CL: cutaneous leishmaniasis; DCL: Diffuse cutaneous leishmaniasis; VL: visceral leishmaniasis; MCL: muco-cutaneous leishmaniasis; PKDL: Post-kala-azar dermal leishmaniasis.
Figure 1Life cycle of Leishmania: some of the wild animals found infected with the parasite are included.
Figure 2PRISMA 2020 flow diagram for the present systematic review.
Wild animals reported infected with zoonotic Leishmania (Viannia) species. Organs or tissues where the parasite was detected are indicated, as well as the techniques employed for detection. L (Viannia) species are as follows: Lb: L. braziliensis, Lg: L. guyanensis, LVsp: Leishmania (Viannia) spp., Lsp: Leishmania sp., Lpa: L. panamensis, Lpe: L. peruviana, Ln: L. naiffi, Ls: L. shawi and Ll: L. lainsoni.
| Host | Prevalence | Organs/Tissue Analysed | Methods for Detection | Country | References | |
|---|---|---|---|---|---|---|
|
| ||||||
| 20–100% | blood, serum | PCR (kDNA), DAT | LVsp | Brazil | [ | |
| 50% | Skin + liver + spleen | Inoculation to hamster, isoenzyme analysis, hybridisation, PCR (kDNA) | Lb | Bolivia | [ | |
| 100% | serum | DAT | LVsp | Brazil | [ | |
| 50% | serum | DAT | LVsp | Brazil | [ | |
| 50% | serum | DAT | LVsp | Brazil | [ | |
|
| ||||||
| 15.6% | blood, LN, liver, skin, spleen | Culture, zymodeme analysis | Lb | Brazil | [ | |
| 100% | blood | PCR (kDNA) | LVsp | Brazil | [ | |
|
| ||||||
| 4.3% | skin | PCR (kDNA), PCR (HSP70) + RFLP, PCR (G6DP) + sequencing | Lb | Brazil | [ | |
| 11.1% | liver, skin | PCR (kDNA), nPCR (SSU) + sequencing | Lb | Brazil | [ | |
| 3.2% | blood | PCR (kDNA), PCR (Cyt B) + sequencing | Lb | Brazil | [ | |
| 5.6% | blood | PCR (kDNA), PCR (Cyt B) + sequencing | Lb | Brazil | [ | |
| 0.9–40% | blood, liver, spleen | PCR (ITS1) + RFLP, PCR (kDNA, PCR (Cyt B) + sequencing | Lb | Brazil | [ | |
| 20% | liver, skin | PCR (kDNA), nPCR (SSU) + sequencing | Lb, LVsp | Brazil | [ | |
| 44–25% | blood | PCR (ITS1) + RFLP, PCR (kDNA), PCR (Cyt b) + sequencing | Lb | Brazil | [ | |
| 13.3% | skin | PCR (kDNA), PCR (HSP70) + RFLP, PCR (G6DP) + sequencing | Lb | Brazil | [ | |
| Several species: | 19.8% | oral swab | PCR (SSU) + sequencing | LVsp | Brazil | [ |
|
| ||||||
| 1.6–50% | blood, BM, liver, serum, skin (tail/ear), spleen | culture, imprints, isoenzymes, PCR (kDNA), qPCR (kDNA) PCR (ITS1), PCR (HSP70), PCR (HSP70) + RFLP, PCR (ITS) + RFLP, nPCR (SSU) + sequencing, IFAT, DAT | Lb, LVsp, Lg, Lpe | Peru, Brazil | [ | |
| 20–33.3% | ear | PCR (kDNA), hybridisation, xenodiagnoses vector | Lb, LVsp | Colombia | [ | |
| 90% | blood | PCR (kDNA), culture | LVsp | Brazil | [ | |
| 16.7–25% | skin, spleen | PCR (kDNA), smears, culture | LVsp | Brazil | [ | |
| 1.4–75% | blood, BM, liver, skin (tail/ear), spleen | PCR (kDNA), PCR (HSP70), PCR (HSP70) + RFLP, PCR (ITS) + RFLP | Lb, LVsp, Lg | Brazil | [ | |
| 50% | ear skin | PCR (HSP70) + RFLP | Brazil | [ | ||
| 66.7% | ear | PCR (kDNA), hybridisation, xenodiagnoses vector | Lb | Colombia | [ | |
|
| 25% | skin, spleen | PCR (kDNA) | LVsp | Brazil | [ |
| 4.2–11.6% | skin | PCR (kDNA), qPCR (kDNA), nPCR (SSU), nPCR (G6DP) | Lb, LVsp | Brazil | [ | |
| 100% | blood | PCR (kDNA) | LVsp or Lsp. | Brazil | [ | |
|
| ||||||
| 100% ( | ear | PCR (kDNA), hybridisation, xenodiagnoses vector | Lb | Colombia | [ | |
|
| ||||||
| 75% | blood | Culture, PCR (kDNA), PCR (HSP70) | Lpa | Panama | [ | |
|
| ||||||
| 8.3% | ear tissue | PCR (ITS) + RFLP + sequencing | Lb, LVsp | Argentina | [ | |
| 44.4% | blood, spleen | PCR (miniexon) + RFLP + sequencing | Lb | Argentina | [ | |
| 100% | blood | PCR (kDNA) | LVsp | Brazil | [ | |
| 100% | serum | DAT | LVsp | Brazil | [ | |
|
| ||||||
| 100% | skin | culture, isoenzymes, inoculation hamster | Ll | Brazil | [ | |
|
| 4% | spleen | smears, PCR (kDNA) | LVsp | Brazil | [ |
|
| 9.7% | liver, skin (tail), spleen | culture (liver and skin), PCR (kDNA) | Lb | Brazil | [ |
| 2.6% | blood, skin | culture + isoenzymes, PCR | LVsp | Peru | [ | |
| 7.8–50% | BM, liver, skin (tail/ear), spleen | culture (skin), PCR (kDNA), PCR (kDNA) + hybridisation, nPCR (SSU) + sequencing, PCR (HSP70) + RFLP | Lb, LVsp | Brazil | [ | |
|
| 3.3% | liver | PCR (kDNA) | LVsp | Brazil | [ |
| 75% | serum | DAT | Brazil | [ | ||
|
| 7.1–15% | skin, spleen | imprints, PCR (kDNA) | LVsp | Brazil | [ |
|
| 21.4% | ear | PCR (kDNA) + hybridisation | Lb | Colombia | [ |
|
| 50% | ear | PCR (kDNA) + hybridisation | Lb | Colombia | [ |
|
| 55–100% | blood, BM, liver, skin (tail/ear), spleen | PCR (kDNA) + RFLP, nPCR (SSU) + sequencing | Lb, LVsp | Brazil | [ |
|
| 4.9–100% | BM, liver, skin (tail/ear), spleen | culture, imprints, PCR (kDNA), PCR (kDNA) + RFLP, serodeme, isoenzyme, PCR (ITS) + RFLP, PCR (D7 24Sα rRNA = trypanosomatids) & PCR (ITS) + sequencing, nPCR (SSU) + sequencing | Lb | Brazil | [ |
|
| 7.2–28.1% | skin, spleen | culture, smears, serodeme, isoenzyme, PCR (ITS) + RFLP, PCR (kDNA), serology rK39 Ag, inoculation to hamster, zymodeme | Lb, LVsp | Brazil | [ |
|
| 100% ( | ear skin | PCR (kDNA) | LV sp | Colombia | [ |
|
| 26.8% | liver | PCR (kDNA) | LV sp | Brazil | [ |
|
| 33.3% | liver | culture, PCR (kDNA), PCR (HSP70) + RFLP | Lb | Brazil | [ |
|
| 1.2% | blood, skin | culture + isoenzymes, PCR | LVsp, Lpe | Peru | [ |
| 100% ( | liver, skin | PCR (kDNA) | LVsp | Brazil | [ | |
|
| 29.6% | ear skin | PCR (D7 24Sα rRNA trypanosomatids) and PCR ITS + sequencing | Lb | Brazil | [ |
| 26.9–66.6% | blood, BM, liver, skin (tail/ear), spleen, | nPCR (SSU) + sequencing | Lb | Brazil | [ | |
| 2.5–50% | blood, BM, liver, skin (tail/ear), spleen | culture, hybridisation, smears, serodeme, isoenzyme, PCR (kDNA), PCR (kDNA) + RFLP, PCR (ITS) + RFLP, nPCR (SSU)+ sequencing, PCR (HSP70) + RFLP, serology rK39 Ag | Lb, LVsp | Brazil, | [ | |
| 0.3%-100% ( | blood, ear skin | culture, PCR (kDNA), PCR (kDNA) + RFLP or hybridisation | Lb, LVsp | Venezuela | [ | |
|
| 6.3–15.6% | liver, skin (tail/ear) | PCR (HSP70) + RFLP | Lb, Lg | Brazil | [ |
|
| 2.5% | spleen | PCR (kDNA), PCR (HSP70) | Ln | Brazil | [ |
|
| 3% | spleen | PCR (kDNA), PCR HSP70 | Ls | Brazil | [ |
|
| 2–3.9% | spleen | PCR (kDNA), PCR (HSP70) | Lb, Ls, Ln, Lg | Brazil | [ |
| 100% ( | blood | PCR (kDNA) | LVsp | Brazil | [ | |
|
| 100% ( | ear skin | PCR (kDNA) | LVsp | Colombia | [ |
BM: bone marrow; Cytb: cytochrome B; DAT: direct agglutination test; FML: fucose-mannose ligand; G6DP: glucose e phosphate dehydrogenase; HSP70: heat shock protein 70 kDa; IHC: immunohistochemistry; IC: immunochromatography; ELISA: enzyme immune assay; IFAT: immunofluorescence assay; ITS: internal transcriber spacer; kDNA: kinetoplast DNA; LN: lymph node; nPCR: nested PCR; qPCR: quantitative PCR; RFLP: restriction fragment length polymorphism; SSU: small subunit of ribosomal RNA.
Wildlife that reported positive for Leishmania amazonensis. Organs or tissues where the parasite was detected are indicated, as well as the techniques employed for detection.
| Host | Prevalence | Organs/Tissue Analysed | Methods for Detection | Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| 50% | liver, skin and spleen | Inoculation to hamster, Isoenzyme typing, PCR (kDNA) PCR (trypanosomatids) + hybridisation | Bolivia | [ | |
|
| |||||
| 1.6% | liver, skin and spleen | nPCR (SSU), qPCR (kDNA), PCR (ITS1) + RFLP | Brazil | [ | |
| n.s. | skin | qPCR (kDNA), PCR (ITS1) + RFLP | Brazil | [ | |
| n.s. | liver, spleen | qPCR (kDNA), PCR (ITS1) + RFLP | Brazil | [ | |
| 8.3% | liver, skin and spleen | nPCR (SSU), qPCR (kDNA), PCR (ITS1) + RFLP | Brazil | [ | |
| 25% | liver, spleen | nPCR (SSU) | Brazil | [ | |
| 5.6% | blood | PCR (kDNA), PCR (Cyt b) + sequencing | Brazil | [ | |
| 2.8–4.2% | blood, liver and spleen | nPCR (SSU), PCR (kDNA), PCR (Cyt B) + sequencing | Brazil | [ | |
| 1–1.6% | blood, liver and spleen | nPCR (SSU), PCR (kDNA), PCR (Cyt B) + sequencing | Brazil | [ | |
| 1% | liver, skin, spleen | nPCR (SSU), qPCR (kDNA), PCR (ITS1) + RFLP | Brazil | [ | |
| 2.9% | liver, spleen | nPCR (SSU), qPCR (kDNA), PCR (ITS1) + RFLP | Brazil | [ | |
| 10% | liver, spleen | nPCR (SSU) | Brazil | [ | |
| 2.9% | blood | PCR (kDNA), PCR (Cyt b) + sequencing | Brazil | [ | |
| 18.2% | blood, spleen | qPCR (kDNA), PCR (ITS1) + RFLP, PCR (kDNA), PCR (Cyt b) + sequencing | Brazil | [ | |
| 25% | liver, spleen | nPCR (SSU) | Brazil | [ | |
|
| |||||
| 1.1% | skin | PCR (kDNA), qPCR (kDNA), nPCR (SSU), PCR (G6PD), sequencing | Brazil | [ | |
|
| |||||
| 2.8% | ear tissue | PCR (ITS) + RFLP + sequencing | Argentina | [ | |
| 100% | blood | PCR (kDNA), PCR (ITS) + RFLP | Brazil | [ | |
|
| |||||
|
| 7.1% | blood | PCR (kDNA) + hybridisation | Bolivia | [ |
| 20% | ear skin | PCR-D7 24Sα rRNA (trypanosomatids) and PCR (ITS) + sequencing | Brazil | [ | |
| 25% | blood | PCR (kDNA) + hybridisation | Bolivia | [ | |
|
| 33.3% | tail skin | PCR (kDNA) + sequencing | Bolivia | [ |
|
| 13.3% | tail skin | PCR (kDNA) + sequencing | Bolivia | [ |
BM: bone marrow; Cyt B: cytochrome B; G6DP: glucose 6 phosphate dehydrogenase; ITS: Internal transcriber spacer; kDNA: kinetoplast DNA; nPCR: nested PCR; n.s.: not specified; qPCR: quantitative PCR; RFLP: restriction fragment length polymorphism; SSU: small subunit of ribosomal RNA.
Wild animals infected with L. mexicana. Organs or tissues where the parasite was detected, as well as the techniques employed, are indicated.
| Host | Prevalence | Organs/Tissue Analysed | Methods for Detection | Country | References |
|---|---|---|---|---|---|
|
| |||||
| 50% | Liver + skin + spleen (macerate) | Inoculation to hamster, isoenzyme analysis, hybridisation | Bolivia | [ | |
| 100% | serum | ELISA | Mexico | [ | |
|
| |||||
|
| 25% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 5.8% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 7.3% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 4.4% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 23.1% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 7.1% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 8.1% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 75% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 26.9% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 50% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 100% ( | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 11.1% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| 4% | heart, liver, skin and spleen | PCR (kDNA), PCR (SSU) | Mexico | [ |
|
| |||||
| 66.7% | base of the tail | PCR (kDNA) | Mexico | [ | |
|
| |||||
| 6.3% | spleen | PCR (ALAT), PCR (ITS1) + sequencing | Mexico | [ | |
|
| |||||
| 5% | serum | ELISA, IFAT and WB | Mexico | [ | |
| 37.5% | serum | ELISA, IFAT and WB | Mexico | [ | |
|
| |||||
|
| 46.3% | base of the tail | PCR (kDNA) | Mexico | [ |
|
| 100% | base of the tail | PCR (kDNA) | Mexico | [ |
| 7.3–50% | skin, ear tissue | Culture, PCR (kDNA), Culture of lesions + PCR + isoenzyme analysis of cultures | USA | [ | |
| 100% | ear, foot | Smears, PCR | USA | [ | |
| 65–100% | skin (base-tail, lesions), liver and spleen | Culture, Mab, imprints and PCR (kDNA) | Mexico | [ | |
|
| 75.5–100% | skin (base-tail), liver | Culture, Mab, imprints and PCR (kDNA) | Mexico | [ |
|
| 100% ( | skin (neck) | PCR (ITS1) + sequencing | USA | [ |
|
| 28.6–100% | skin (base-tail), heart and kidney, liver, spleen | Culture, PCR (kDNA) and imprints | Mexico | [ |
| 2.9–19% | blood | Culture, PCR (kDNA) + RFLP/hybridisation | Venezuela, Brazil | [ | |
|
| 66.6% | skin (base-tail) | Culture, PCR (kDNA) | Mexico | [ |
| 58.8–100% | liver, skin (base-tail, lesion) and spleen | Imprints, culture, Mab and PCR (kDNA) | Mexico | [ | |
|
| 27.8% | blood | PCR (kDNA) + hybridisation | Brazil | [ |
ALAT: alanine transaminase; ELISA: enzyme immune assay; IFAT: Immunofluorescence assay; ITS: internal transcriber spacer; kDNA: kinetoplast DNA; Mab: monoclonal antibodies; SSU: small subunit of ribosomal RNA.
Wild animals infected with L. infantum (sin. L. chagasi) and Leishmania spp. in the Americas. Organs or tissues positive to the parasite, as well as techniques employed, are indicated.
| Host | Prevalence | Organs/Tissue Analysed | Method of Detection | Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| 4–100% | BM, heart, liver, lung, mesenteric LN, serum skin and spleen | Smears, ELISA, culture, PCR, inoculation to hamster, IFAT, xenodiagnosis vector, PCR (kDNA) + sequencing, PCR (kDNA) + sequencing * | Brazil | [ | |
| 10–75% | BM, serum and skin | ELISA, IFAT, PCR (kDNA), PCR (kDNA) + sequencing, IC rk39, xenodiagnoses in vector | Brazil | [ | |
| n.s. | serum | DAT ( | Brazil | [ | |
| n.s. | serum | DAT ( | Brazil | [ | |
| 75% | serum | ELISA, | Brazil | [ | |
| 33.3% | BM, serum | IFAT, ELISA, PCR (kDNA) | Brazil | [ | |
| n.s. | serum | DAT ( | Brazil | [ | |
| 33.3–100% | blood, LN, serum, skin, spleen and other tissues (liver, kidney, lung and large intestine) | PCR (kDNA), PCR (kDNA) + sequencing, histopathology, IHC, ELISA, IFAT, IC rk39, xenodiagnoses in vector | Brazil | [ | |
| 20–50% | blood, LN and serum | PCR (kDNA) + RFLP, ELISA, IC | Brazil | [ | |
| 50% | serum | ELISA, IC | Brazil | [ | |
| 50–100% | blood, serum | PCR (kDNA) + RFLP, ELISA | Brazil | [ | |
| 71.4% | blood, LN | PCR (kDNA) + RFLP | Brazil | [ | |
| 33.3% | kidney | PCR (kDNA) + sequencing * | Brazil | [ | |
|
| |||||
| 7.4–16.7% | blood | PCR (kDNA), PCR (Cyt B) + sequencing | Brazil | [ | |
| 40.9% | blood | qPCR (kDNA) | Brazil | [ | |
| 50% | liver, skin | qPCR (kDNA), PCR (ITS1) + RFLP, PCR (kDNA), nPCR (SSU) + sequencing | Brazil | [ | |
| 3–27.3% | blood, spleen | Culture, qPCR (kDNA) | Venezuela, Brazil and French Guiana | [ | |
| 11.1% | blood | PCR (kDNA), PCR (Cyt B) + sequencing | Brazil | [ | |
| 100% ( | blood | PCR (kDNA), PCR (Cyt B) + sequencing | Brazil | [ | |
| 0.7–100% | blood, liver and spleen | nPCR (SSU), PCR (kDNA), PCR (Cyt B) + sequencing, qPCR (kDNA), PCR (kDNA) and nPCR (SSU) + sequencing | Brazil | [ | |
| 33.3% | liver | PCR (kDNA) + nPCR (SSU) + sequencing | Brazil | [ | |
| 0.5%–100% | blood, liver and spleen | nPCR (SSU), qPCR (kDNA), PCR (ITS1) + RFLP, PCR (kDNA), PCR (Cyt B) + sequencing, PCR (kDNA) + nPCR (SSU) + sequencing | Brazil | [ | |
| 21.1% | liver, skin | PCR (kDNA) + nPCR (SSU) + sequencing | Brazil | [ | |
| 20–100% | liver, spleen | qPCR (kDNA), PCR (ITS1) + RFLP, nPCR (SSU) + sequencing | Brazil | [ | |
| 40% | liver, skin | PCR (kDNA)+ nPCR (SSU) + sequencing | Brazil | [ | |
| 40% | liver, skin | PCR (kDNA) and nPCR (SSU) + sequencing | Brazil | [ | |
| 60% | liver, skin | PCR (kDNA) + nPCR (SSU) + sequencing | Brazil | [ | |
| 15.4% | blood | qPCR (kDNA) | Brazil | [ | |
| 5.9% | blood | PCR (kDNA), PCR (Cyt B) + sequencing | Brazil | [ | |
| 100% ( | blood | qPCR (kDNA) | Brazil | [ | |
| 100% ( | blood | PCR (SSU), PCR (GAPDP) | Brazil | [ | |
| 0.1% | oral swab | PCR (SSU) + sequencing * | Brazil | [ | |
|
| |||||
| 100% ( | liver | PCR (kDNA) + sequencing * | Brazil | [ | |
|
| |||||
| 6.3–22.2% | blood, BM, liver, lung, kidney, skin and spleen | Culture, PCR (ITS1) + RFLP, PCR (kDNA), PCR (kDNA) + sequencing, nPCR (SSU) + sequencing, PCR (kDNA), PCR (ITS1) | Brazil | [ | |
| 6.3% | LN, serum and spleen | Spleen smears, PCR (kDNA) + hybridisation IC rk39 | Brazil | [ | |
| 7.1–40.5% | blood, BM, liver, serum, skin and spleen | smears, Culture, inoculation to hamster + isoenzyme, Mab, PCR (kDNA) + hybridisation, IFAT, DAT, PCR+RFLP, nPCR (SSU), PCR (ITS1) | Brazil, Colombia and Venezuela | [ | |
| 91.6% | blood, BM | PCR (kDNA) ELISA, FML-ELISA, smears, culture | Brazil | [ | |
|
| |||||
| n.s. | serum | DAT (n = 1) | Brazil | [ | |
|
| |||||
| 33.3% | heart, kidney, lung and mesenteric LN | PCR (kDNA) + sequencing * | Brazil | [ | |
| 50–100% | BM, liver, lung and mesenteric LN | PCR (kDNA), PCR (ITS1) + sequencing | Brazil | [ | |
|
| |||||
| 3.7% | ear tissue | PCR (ITS) + RFLP + sequencing | Brazil, Argentina | [ | |
| 12.5 | blood | PCR (kDNA) | Brazil | [ | |
| 22.2% | blood | PCR (kDNA), PCR (ITS2), PCR (SSU), IC | French Guiana | [ | |
| 100% ( | blood | qPCR (kDNA) | Brazil | [ | |
| 33.3% | blood, liver, lung, intestine and spleen | qPCR (kDNA), IHC, | Brazil | [ | |
| 100% ( | serum | DAT | Brazil | [ | |
|
| 26.9% | blood, skin | DAT, PCR + sequencing | Brazil | [ |
| 60% | blood | qPCR (kDNA) | Brazil | [ | |
| 20% | blood | qPCR (kDNA) | Brazil | [ | |
| 50% | blood | qPCR (kDNA) | Brazil | [ | |
| 100% | blood | qPCR (kDNA) | Brazil | [ | |
|
| |||||
| 25% | heart | PCR (kDNA) + sequencing | Brazil | [ | |
|
| 25% | BM, liver and spleen | nPCR (SSU) + sequencing | Brazil | [ |
| n.s. | serum | DAT ( | Brazil | [ | |
| 20% | heart, kidney, liver and spleen | PCR (kDNA) + sequencing | Brazil | [ | |
|
| 5.2% | spleen | PCR (kDNA) + PCR (HSP70) | Brazil | [ |
|
| 16.7% | spleen | PCR (kDNA) + PCR (HSP70) | Brazil | [ |
| n.s. | blood, skin | PCR (kDNA) + PCR (ITS), PCR (HSP70) + sequencing | Brazil | [ | |
|
| 10% | skin, spleen | PCR (kDNA) | Brazil | [ |
| 50% | lung | PCR (kDNA) + sequencing | Brazil | [ | |
| 20% | BM, liver, tail–ear skin and spleen | nPCR (SSU) + sequencing | Brazil | [ | |
|
| 7% | skin, spleen | PCR (kDNA) | Brazil | [ |
|
| 8.8% | skin, spleen | PCR + hybridisation | Colombia | [ |
|
| n.s. | blood, skin | PCR (kDNA) + PCR (ITS), PCR (HSP70) + sequencing | Brazil | [ |
|
| 28.5% | liver | PCR (HSP70) + RFLP | Brazil | [ |
| 16.7% | liver, tail–ear skin, | nPCR (SSU) + sequencing | Brazil | [ | |
| 0.1–100% | blood, BM, liver, skin and spleen | PCR (kDNA), PCR (kDNA) + hybridisation, PCR (HSP70) + RFLP, PCR (kDNA), nPCR (SSU) + sequencing, PCR (HSP70) + RFLP | Venezuela | [ | |
|
| 6.3–11.1% | skin, ear skin | PCR (kDNA) + hybridisation PCR (HSP70) + RFLP | Brazil | [ |
|
| 1% | spleen | PCR (kDNA) | Brazil | [ |
| Wild animals infected with | |||||
|
|
|
|
|
|
|
|
| |||||
| 1.6% | serum | IC rAgK39 | USA | [ | |
| 15.3–100% | blood, serum and skin | qPCR (kDNA), IFAT, IC | Brazil | [ | |
| 42.9% | blood | qPCR (kDNA) | Brazil | [ | |
| 50% | blood | qPCR (kDNA) | Brazil | [ | |
| 37.5% | blood | PCR (kDNA) + sequencing | Argentina | [ | |
| 7.1–50% | blood, serum | qPCR (kDNA), IFAT | Brazil | [ | |
| 50% | blood | qPCR (kDNA), IFAT | Brazil | [ | |
| 100% ( | blood | qPCR (kDNA) | Brazil | [ | |
| 33.3–100% | Blood, serum, liver and LN | ELISA, PCR (kDNA) | Brazil | [ | |
| 9.1% | serum | IC rK39 | USA | [ | |
| 2% | serum | IC rK39 | USA | [ | |
|
| |||||
| 7.4% | liver | PCR (kDNA)+ nPCR (SSU) + sequencing | Brazil | [ | |
| 5.2% | liver | PCR (kDNA)+ nPCR (SSU) + sequencing | Brazil | [ | |
| 6.7% | liver | PCR (kDNA)+ nPCR (SSU) + sequencing | Brazil | [ | |
|
| |||||
| 36.4% | blood | qPCR (kDNA) | Brazil | [ | |
| 33.3% | blood | qPCR (kDNA) | Brazil | [ | |
|
| |||||
| 37.5% | blood | PCR (kDNA) | Brazil | [ | |
| 20% | blood | qPCR (kDNA) | Brazil | [ | |
| 50% | blood | qPCR (kDNA) | Brazil | [ | |
| 33.3% | blood | qPCR (kDNA) | Brazil | [ | |
| 16.7% | blood | qPCR (kDNA) | Brazil | [ | |
|
| |||||
| 9.1% | serum | IFAT | Dominican Republic | [ | |
| 100% ( | blood | nPCR (SSU) | Venezuela | [ | |
BM: bone marrow; Cyt B: cytochrome B; DAT: direct agglutination test; FML: fucose-mannose ligand; GADPH: glyceraldehyde phosphate dehydrogenase; HSP70: heat shock protein 70kDa; IHC: immunohistochemistry; IC: immunochromatography; ELISA: enzyme immune assay; IFAT: immunofluorescence assay; ITS: internal transcriber spacer; kDNA: kinetoplast DNA; LN: lymph node; nPCR: nested PCR; n.s.: not specified; qPCR: quantitative PCR; RFLP: restriction fragment length polymorphism; SSU: small subunit of ribosomal RNA. * Probably L. infantum, according to the sequence.
Wild animals reported to be positive for L. infantum from Europe, Asia and Africa. Organs or tissues where the parasite was detected are indicated, as well as the techniques employed for detection.
| Host | Prevalence | Organs/Tissue Analysed | Methods for Detection | Country | References |
|---|---|---|---|---|---|
|
| |||||
| 3–11.6% | blood, BM, liver, LN, serum, spleen | qPCR (ITS1), PCR (kDNA), IC rk39, smear, culture, PCR (α-tubulin and GAPDH) | Georgia, Israel, Iran and Romania | [ | |
| 6–100% | blood, hair, liver, LN, skin, serum, spleen | PCR (cysteine protease B), qPCR (kDNA), PCR (kDNA) + RFLP, PCR (ITS2) + RFLP, PCR (kDNA) + sequencing, ELISA | Croatia, Italy, Spain | [ | |
| 25–100% | liver, LN, skin, spleen | qPCR (kDNA), PCR (ITS2) + sequencing, PCR (kDNA) + sequencing, qPCR (kDNA) + RFLP + sequencing | Spain | [ | |
| 10–100% | blood, liver, skin and spleen | PCR (kDNA) + RFLP, qPCR (kDNA), PCR (ITS2) + sequencing, PCR (kDNA) + sequencing, qPCR (kDNA) + RFLP + sequencing, PCR (kDNA & ITS2) + RFLP | Spain | [ | |
| 4.7–28.6% | blood, spleen, | PCR (kDNA) + RFLP, PCR (kDNA) + sequencing, PCR (ITS1) | Spain, Portugal | [ | |
| 70% | spleen | PCR (kDNA) + sequencing | Spain | [ | |
| 25% | blood, spleen, | PCR (kDNA) + RFLP | Spain | [ | |
| 29–100% | liver, LN, hair, skin and spleen | qPCR (kDNA), qPCR (ITS2) + sequencing, PCR (kDNA) + sequencing, qPCR (kDNA) + sequencing, PCR (kDNA & ITS2) + RFLP | Spain | [ | |
| 30–62% | blood, liver, spleen | PCR (kDNA) + RFLP, qPCR (kDNA), qPCR (ITS2) + sequencing, PCR (kDNA) + sequencing | Spain | [ | |
| 26–53% | liver, spleen | qPCR (kDNA), PCR (ITS2) + sequencing, PCR (kDNA) + sequencing | Spain, Italy | [ | |
| 2.1–50% | liver, spleen, serum | qPCR (kDNA), PCR (ITS2) + sequencing, PCR (ITS1), ELISA | Greece, Spain | [ | |
| 25% | liver, spleen | qPCR (kDNA), PCR (ITS2) + sequencing | Spain | [ | |
| 100% ( | liver, spleen | qPCR (kDNA) | Spain | [ | |
| 25% | serum, LN and swab (oral, conjunctival and nasal) | IFAT, qPCR | Italy | [ | |
| 20% | liver, skin, pleen | qPCR (kDNA) | Spain | [ | |
| 100% ( | liver, skin, spleen | PCR (kDNA), PCR (ITS2) + RFLP | Spain | [ | |
| 2.6–74.6% | blood, BM, hair, liver, LN, skin, spleen, serum | PCR (Repeat Region), PCR (kDNA), PCR (kDNA) + RFLP, qPCR (kDNA), qPCR (ITS2) + sequencing, qPCR (ITS1) + RFLP, PCR (α-tubulin and GAPDH) + sequencing, PCR (kDNA) + RFLP, PCR (kDNA) + sequencing, PCR (ITS2) + RFLP, PCR (ITS1) + sequencing, ELISA, IFAT, WB, IC rk39, smear, culture | France, Georgia and Greece, Iran, Italy and Spain | [ | |
|
| |||||
| 59.2% | blood clot, hair, spleen | PCR (Repeat region) + sequencing | Spain | [ | |
| Order Diprotodontia | |||||
| 33.3% | blood, BM, liver, lung, LN, kidney, skin, spleen | PCR (ITS1 and ITS2) + sequencing, IC rk39 | Spain | [ | |
|
| |||||
| 100% | blood, eye swab, heart, kidney, liver, LN, skin, spleen | PCR (kDNA), PCR (ITS1), PCR (mini-exon), PCR (Repeat region), PCR (SSU), smear | Tunisia | [ | |
| 34.4–100% | hair, serum, skin, spleen | qPCR (kDNA), ELISA | Spain | [ | |
|
| |||||
| 0.9–43.6% | blood, spleen, serum | PCR (kDNA) + RFLP, PCR (ITS1), PCR (ITS1) + sequencing, ELISA, IFAT | Greece, Italy and Spain | [ | |
| 10.1–100% | hair, skin, spleen, serum | PCR (kDNA) + RFLP, qPCR (kDNA), nPCR (SSU), IFAT, DFA | Spain | [ | |
| 0.6–59% | blood, BM, hair, heart, liver, LN, skin, spleen, serum | qPCR (kDNA), PCR (ITS1) + RFLP, ELISA, nPCR (SSU), qPCR (kDNA) + RFLP + sequencing, PCR (kDNA) + RFLP, PCR (ITS2) + RFLP, PCR (ITS1), smears, culture, IFAT, DFA, ELISA, IC rk39 | Greece, Italy and Spain | [ | |
|
| |||||
| 100% | BM, serum | Microscopy, IFAT, nPCR (ITS1) | Spain | [ | |
|
| |||||
| 20–50% | blood, BM, liver, skin, spleen | PCR (ITS1) + sequencing, PCR-ELISA (kDNA), qPCR (kDNA) + RFLP + sequencing, PCR (ITS2) + RFLP, smear, culture | Spain | [ | |
| 13.3% | blood and/or spleen | qPCR (kDNA) | Spain | [ | |
| 22–50% | blood, BM, liver, skin, spleen | qPCR (kDNA) + sequencing, PCR (ITS1) + sequencing, PCR-ELISA (kDNA), nPCR (SSU and ITS1) + sequencing, smear | Morocco, Portugal and Spain | [ | |
| 4.3–42.9% | blood, liver, skin, spleen and serum | qPCR (kDNA), ELISA | Spain | [ | |
| 39% | liver, skin, spleen, | nPCR (kDNA), smear | Iran | [ | |
| 5.9–100% | hair, liver, skin, spleen | nPCR (SSU), nPCR (ITS1) + sequencing, qPCR (kDNA), PCR (kDNA), PCR (kDNA) + RFLP, PCR (ITS2) + RFLP, smear | Greece, Morocco, Portugal and Spain | [ | |
| 7.5–33.3% | blood, BM, liver, skin, spleen | PCR (kDNA) + sequencing, PCR (ITS1) + sequencing, PCR-ELISA (kDNA), nPCR (SSU), nPCR (ITS1) + sequencing, smear, culture, inoculation to hamster, isoenzymes | Italy, Morocco, Saudi Arabia and Spain | [ |
BM: bone marrow; Cyt b: cytochrome B; DFA: direct fluorescence antibody assay; GADPH: glyceraldehyde phosphate dehydrogenase; IC: immunochromatography; ELISA: enzyme immune assay; IFAT: immunofluorescence assay; ITS: internal transcriber spacer; kDNA: kinetoplast DNA; LN: lymph node; nPCR: nested PCR; qPCR: quantitative PCR; RFLP: restriction fragment length polymorphism; SSU: small subunit of ribosomal RNA; WB: Western blot.
Wild animals reported positive for L. major. Organs or tissues where the parasite was detected, and the techniques employed are indicated.
| Host | Prevalence | Organs/Tissue Analysed | Methods for Detection | Country | References |
|---|---|---|---|---|---|
|
| |||||
|
| 100% ( | spleen | qPCR (kDNA and ITS1) + sequencing | Ethiopia | [ |
|
| |||||
| 36.8–100% | blood, eye swab, heart, kidney, liver, LN, skin, spleen | qPCR (kDNA), PCR (kDNA), PCR (ITS1) + RFLP, nPCR (kDNA), PCR (ITS1) + sequencing + RFLP, PCR (mini-exon) + sequencing + RFLP, nPCR (Repeat region) + sequencing + RFLP, PCR (SSU) + sequencing, smear, ELISA, WB | Algeria, Tunisia | [ | |
| 33.3–53.3% | liver, skin, spleen | nPCR (ITS1) + sequencing, nPCR (kDNA), semi-nPCR (kDNA), smear | Iran | [ | |
| 40–100% | blood, eye swab, kidney, liver, LN, skin, spleen, serum | qPCR (kDNA), PCR (ITS1) + RFLP, PCR (kDNA and SSU) + sequencing, nPCR (Repeat region) + RFLP + sequencing, ELISA, WB | Algeria, Tunisia | [ | |
|
| |||||
| 67.2% | serum | ELISA, WB | Kenya | [ | |
| 60.6% | serum | ELISA, WB, lymphocyte proliferation assay | Kenya | [ | |
| 13.2% | faeces | qPCR (SSU), qPCR (SSU) + sequencing, PCR (ITS) + sequencing, PCR (Cytb) + sequencing | Cameroon | [ | |
| 77.2% | serum | ELISA, WB | Kenya | [ | |
|
| |||||
|
| 11.8% | liver, skin, spleen | PCR (kDNA), smear | Iran | [ |
|
| 7.7% | liver, skin, spleen | PCR (kDNA), smear | Iran | [ |
|
| 5.7–100% | liver, skin, spleen | PCR (kDNA), nPCR (ITS1), PCR (ITS1) + RFLP + sequencing, semi-nPCR (kDNA), PCR (Cytb) + sequencing, nPCR (ITS1) + sequencing, nPCR (ITS2) + RFLP, smear, inoculation to hamster, inoculation to BALB/c mice | Iran | [ |
|
| 33% | skin | PCR (ITS1) + RFLP + sequencing, smear | Iran | [ |
|
| 58.3% | skin | PCR (ITS1) + RFLP | Israel | [ |
|
| 16.5% | skin | PCR (ITS1) + RFLP | Israel | [ |
|
| 50% | liver, skin, spleen | smear | Iran | [ |
| 2.3–33% | liver, skin, spleen | PCR (ITS1) + RFLP, smear | Israel, Morocco and Iran | [ | |
|
| 8–63.4% | liver, skin, spleen | PCR (ITS1) + RFLP + sequencing, PCR (kDNA), nPCR (kDNA), smear | Iran | [ |
| 13.4–35% | skin | PCR (ITS1) + RFLP + sequencing, semi-nPCR (kDNA), PCR (Cytb) + sequencing, smear, IHC, inoculation to hamster, inoculation to BALB/c mice | Iran | [ | |
|
| 3.7–50% | liver, skin, spleen | PCR (kDNA), PCR (ITS1) + RFLP + sequencing, semi-nPCR (kDNA) + sequencing, PCR (Cytb), smear | Iran | [ |
Cytb: cytochrome B; IHC: immunohistochemistry; ELISA: enzyme immune assay; ITS: internal transcriber spacer; kDNA: kinetoplast DNA; LN: lymph node; nPCR: nested PCR; qPCR: quantitative PCR; RFLP: restriction fragment length polymorphism; SSU: small subunit of ribosomal RNA; WB: Western blot.